Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) news page on Stock Titan aggregates company announcements, clinical updates, financial results, and corporate developments for this commercial-stage oncology biopharmaceutical company. Day One describes itself as dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, with a strong emphasis on pediatric cancer and rare cancers.
Investors and followers of DAWN can use this news feed to review updates on OJEMDA™ (tovorafenib), Day One’s Type II RAF kinase inhibitor indicated for certain BRAF-altered pediatric low-grade gliomas. Company press releases cover pivotal and follow-up data from the FIREFLY-1 Phase 2 trial, the ongoing FIREFLY-2/LOGGIC Phase 3 trial in front-line pLGG, and regulatory designations such as Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug status described in Day One’s communications.
The feed also captures financial results and guidance, including OJEMDA net product revenue trends, license revenue from ex-U.S. commercial rights, and reported cash, cash equivalents, and short-term investments. These updates are often accompanied by conference call details and investor presentations referenced in the company’s Form 8-K filings.
Another important category of DAWN news involves pipeline and portfolio developments. This includes progress in the Phase 1a/1b trial of DAY301, a PTK7-targeted antibody-drug conjugate, and the addition of Emi-Le (emiltatug ledadotin), a B7-H4–targeted ADC for adenoid cystic carcinoma, through the acquisition of Mersana Therapeutics. Corporate announcements around this acquisition, as well as participation in industry and investor conferences such as the J.P. Morgan Healthcare Conference and the Piper Sandler Healthcare Conference, are also reflected.
By reviewing this curated stream of official press releases and related disclosures, users can follow how Day One reports clinical milestones, commercial performance for OJEMDA, and strategic decisions that shape its oncology pipeline. Bookmarking the DAWN news page provides a centralized view of these developments as they are released.
Day One (Nasdaq: DAWN) reported preliminary unaudited 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, with Q4 2025 revenue of $52.8 million (~37% QoQ growth) and 1,394 prescriptions in Q4. The company provided 2026 OJEMDA U.S. net product revenue guidance of $225–$250 million (midpoint ≈ 53% YoY growth). As of Dec 31, 2025, prior to the Mersana acquisition, Day One held approximately $441.1 million of cash, cash equivalents, and short-term investments (unaudited). Key near-term milestones include completing Phase 3 FIREFLY-2 enrollment in 1H 2026 (mid-2027 readout) and planned Phase 1 data for Emi-Le by mid-2026 and DAY301 in 2H 2026.
Day One (Nasdaq: DAWN) completed its acquisition of Mersana Therapeutics on January 6, 2026, acquiring all outstanding shares for $25 per share in cash plus one non-tradable contingent value right (CVR) per share for potential milestone payments up to $30.25 per CVR, for total consideration of up to $55.25 per share.
The tender offer expired Jan. 5, 2026 with 3,029,135 shares validly tendered (representing 60.57% of Mersana outstanding). Following a statutory merger under Delaware law, Mersana became a direct wholly owned subsidiary of Day One and its Nasdaq common stock will be delisted prior to market open on Jan. 6, 2026. Day One adds clinical-stage ADC emiltatug ledadotin (Emi-Le), targeting B7-H4 and adenoid cystic carcinoma (ACC), to its pipeline.
Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET. A live audio webcast will be available via the company’s News & Events web page and an archived replay will be accessible for 30 days after the live presentation.
Day One (Nasdaq: DAWN) reported three-year follow-up data from the Phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib) in relapsed/refractory pediatric low-grade glioma (data cutoff June 6, 2025; median study duration 40.6 months).
Key results in 76 evaluable patients: overall response rate 53%, median duration of response 19.4 months, median PFS 16.6 months, and median time-to-next-treatment 42.6 months. Of 39 patients entering treatment-free observation, 77% remained off therapy ≥12 months. No new safety signals; Grade ≥3 events (≥5%) listed.
Day One (Nasdaq: DAWN) announced management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:00 p.m. EST.
A live webcast will be available via the Events section of the Day One Media & Investors page, and an archived replay will be available for 30 days after the live event.
Day One (NASDAQ: DAWN) signed a definitive merger agreement to acquire Mersana Therapeutics for $25 per share cash plus one non-tradable CVR, with total consideration up to $55.25 per share and an approximate equity value at closing of $129 million (total deal value up to ~$285 million). The acquisition adds emiltatug ledadotin (Emi-Le), an antibody‑drug conjugate targeting B7-H4, which showed early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type‑1 (ACC‑1).
Milestone CVR payments total up to $30.25 per share tied to clinical, regulatory, and sales milestones. Day One expects to fund the transaction with existing cash and aims to close by end of January 2026, subject to regulatory approvals and customary conditions.
Day One (Nasdaq: DAWN) will present new long‑term data for OJEMDA (tovorafenib) from the registrational Phase 2 FIREFLY-1 trial at the 30th SNO Annual Meeting on November 23, 2025. The oral presentation reports >36‑month follow‑up in patients aged 6 months–25 years with relapsed or progressive pediatric low‑grade glioma and will include treatment‑free interval (TFI) data disclosed for the first time.
The presentation covers once‑weekly oral monotherapy after completion of a full course of 26 cycles (~24 months); an earlier data cut is in the abstract and updated results will be shown at the meeting in Honolulu.
Day One (Nasdaq: DAWN) reported third quarter 2025 results with accelerating commercial performance of OJEMDA and strengthened financial position. Q3 OJEMDA net product revenue was $38.5M, up 15% sequentially; YTD U.S. OJEMDA revenue was $102.6M, +89% versus 2024. Quarterly TRx reached 1,256 and new patient starts rose 19% sequentially. The company raised full-year 2025 OJEMDA revenue guidance to $145–$150M. R&D spend was $31.4M and SG&A $28.1M in Q3; net loss was $19.7M. Cash, cash equivalents and short-term investments totaled $451.6M as of Sep 30, 2025. Three-year FIREFLY-1 data will be presented Nov 23, 2025.
Day One Biopharmaceuticals (Nasdaq: DAWN) will report its third quarter 2025 financial results on Tuesday, November 4, 2025.
The company will host a live conference call and webcast on Nov. 4, 2025 at 4:30 p.m. ET to discuss results and corporate progress. Live audio will be available in the Events section of Day One's Media & Investors page, and an archived replay will be accessible for 30 days after the event.
Day One Biopharmaceuticals (NASDAQ:DAWN) reported strong Q2 2025 financial results, with OJEMDA net product revenue of $33.6 million, representing a 310% increase year-over-year and 10% quarter-over-quarter growth. The company provided full-year 2025 OJEMDA revenue guidance of $140-150 million.
Key highlights include OJEMDA prescriptions exceeding 1,000 in Q2 2025 (up 346% YoY), appointment of Dr. Michael Vasconcelles as Head of R&D, and continued progress in clinical trials. The company ended Q2 with $453.1 million in cash and reported a net loss of $30.3 million. R&D expenses decreased to $36.1 million from $92.1 million in Q2 2024, primarily due to prior year's MabCare license payment.
FAQ
What is the current stock price of Day One Biopharmaceuticals (DAWN)?
What is the market cap of Day One Biopharmaceuticals (DAWN)?
